FLUI Stock Overview
Fluicell AB (publ) operates as a life science company, provides platforms and research solutions for bioprinting and single-cell biology.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Fluicell AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.10 |
| 52 Week High | kr2.80 |
| 52 Week Low | kr0.093 |
| Beta | 1.68 |
| 1 Month Change | -22.09% |
| 3 Month Change | -81.73% |
| 1 Year Change | -96.15% |
| 3 Year Change | -99.69% |
| 5 Year Change | -98.75% |
| Change since IPO | -99.34% |
Recent News & Updates
Shareholder Returns
| FLUI | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -5.2% | 1.6% | 1.8% |
| 1Y | -96.1% | -9.0% | 10.7% |
Return vs Industry: FLUI underperformed the Swedish Medical Equipment industry which returned -9% over the past year.
Return vs Market: FLUI underperformed the Swedish Market which returned 10.7% over the past year.
Price Volatility
| FLUI volatility | |
|---|---|
| FLUI Average Weekly Movement | 24.0% |
| Medical Equipment Industry Average Movement | 6.9% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 12.9% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: FLUI's share price has been volatile over the past 3 months.
Volatility Over Time: FLUI's weekly volatility has decreased from 30% to 24% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 17 | Victoire Viannay | www.fluicell.com |
Fluicell AB (publ) operates as a life science company, provides platforms and research solutions for bioprinting and single-cell biology. The company offers BIOPEN, a microfluidic platform for high-precision single-cell solution delivery that enables to control the cell microenvironment without moving or disturbing the cells; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch-clamp recording configuration. It also provides Biopixlar, a 3D single-cell bioprinting platform that enables high cell viability and cell-to-cell communication; and Biopixlar AER, an easy-to-use 3D bioprinting platform that fits into your fume hood or biosafety cabinet.
Fluicell AB (publ) Fundamentals Summary
| FLUI fundamental statistics | |
|---|---|
| Market cap | kr33.01m |
| Earnings (TTM) | -kr26.55m |
| Revenue (TTM) | kr3.34m |
9.9x
P/S Ratio-1.2x
P/E RatioIs FLUI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FLUI income statement (TTM) | |
|---|---|
| Revenue | kr3.34m |
| Cost of Revenue | kr1.60m |
| Gross Profit | kr1.74m |
| Other Expenses | kr28.29m |
| Earnings | -kr26.55m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 10, 2024
| Earnings per share (EPS) | -0.081 |
| Gross Margin | 52.07% |
| Net Profit Margin | -795.51% |
| Debt/Equity Ratio | 0% |
How did FLUI perform over the long term?
See historical performance and comparison